Sargassum pallidum polypeptide effervescent tablet and preparation method thereof
By preparing effervescent tablets of Artemisia annua polypeptides, the standardization problem of Artemisia annua active ingredient preparations in existing technologies has been solved, providing a highly efficient, stable, and palatable marine functional food and medicine suitable for specific populations, and realizing the high-value utilization of Artemisia annua polypeptides.
Patent Information
- Application Number
- CN202511406091.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-23
- Publication Date
- 2025-11-18
AI Technical Summary
In the current technology, the research on formulations of active ingredients from Artemisia annua is relatively limited, and there is a lack of standardized and regulated methods for preparing effervescent tablets, which makes it difficult to meet the needs of children, the elderly, and patients with swallowing difficulties.
Effervescent tablets of Artemisia annua polypeptide are prepared by mixing, drying and tableting processes using a composition of 20%–30% Artemisia annua polypeptide, 15%–22% diluent, 20%–30% anhydrous citric acid, 25%–33% alkaline disintegrant, 0.1%–1.0% lubricant and 0.1%–1.0% flavoring agent, ensuring the proportion of each component and the stability of the process.
This invention provides a stable, quality-controllable, and palatable effervescent tablet of Artemisia annua polypeptide, suitable for children, the elderly, and people with swallowing difficulties, thereby enhancing the high-value utilization of Artemisia annua and the development of marine functional foods and medicines.
Smart Images
Figure BSA0000301595080000041 
Figure BSA0000301595080000051
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical preparation technology, specifically relating to an effervescent tablet of Artemisia annua polypeptide and its preparation method. Background Technology
[0002] Sargassum pallidum is a common marine brown algae widely distributed along the coast of my country, with a long history of medicinal and edible use. Modern research shows that Sargassum pallidum is rich in various bioactive components, including polysaccharides, polypeptides, polyphenols, and minerals, possessing multiple physiological functions such as antioxidation, antitumor activity, immunomodulation, and lipid-lowering effects. Among these, Sargassum pallidum polypeptides, as one of its important active ingredients, have received widespread attention in recent years due to their small molecular weight, easy absorption, and high bioavailability.
[0003] Effervescent tablets, as a special type of oral solid dosage form, have the advantages of convenient administration, rapid onset of action, and high bioavailability, making them particularly suitable for children, the elderly, and patients with difficulty swallowing.
[0004] Currently, research on the active ingredients of Artemisia annua mainly focuses on extraction processes, activity evaluation, and the application of crude extracts, while research on its further development into standardized and regulated formulations remains relatively limited.
[0005] This invention provides a seaweed polypeptide effervescent tablet with a reasonable formula, stable process, controllable quality, and good taste. It not only helps to promote the high-value utilization of seaweed, but also provides new directions and technical support for the development of marine-derived functional foods and medicines. Summary of the Invention
[0006] The technical problem to be solved by the present invention is to address the shortcomings of the prior art by providing a seaweed seed polypeptide effervescent tablet and its preparation method.
[0007] To achieve the objectives of this invention, the following technical means are specifically employed:
[0008] A type of effervescent tablet containing seaweed polypeptide, characterized in that it comprises the following components in weight percentage: 20%–30% seaweed polypeptide, 15%–22% diluent, 20%–30% anhydrous citric acid, 25%–33% alkaline disintegrant, 0.1%–1.0% lubricant, and 0.1%–1.0% flavoring agent; wherein the alkaline disintegrant is selected from sodium bicarbonate or sodium carbonate; and the sum of the weight percentages of all components is 100%.
[0009] The aforementioned Artemisia annua polypeptide effervescent tablets are characterized in that: the diluent is selected from at least one of xylitol, lactose, and microcrystalline cellulose.
[0010] The aforementioned Artemisia annua polypeptide effervescent tablet is characterized in that: the lubricant is selected from at least one of polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000.
[0011] The aforementioned seaweed polypeptide effervescent tablets are characterized in that: the flavoring agent is selected from at least one of steviol glycosides, strawberry flavoring, and orange flavoring.
[0012] The aforementioned Artemisia annua polypeptide effervescent tablet is characterized in that the mass ratio of the alkaline disintegrant to anhydrous citric acid is (1.11-1.51):1.
[0013] The preparation method of the Artemisia annua polypeptide effervescent tablets is characterized by comprising the following steps:
[0014] (a) The acidic components (anhydrous citric acid and 50% of the prescribed amount of Artemisia annua polypeptide) were mixed with a wetting agent, granulated, dried, and sized to obtain acid granules;
[0015] (b) The alkaline component (alkaline disintegrant and 50% of the prescribed amount of Artemisia annua polypeptide) is mixed with a wetting agent, granulated, dried, and granulated to obtain alkaline granules;
[0016] (c) Mix the acid particles, alkali particles, diluent, lubricant, and flavoring agent evenly;
[0017] (d) Compress the tablets to obtain the final product.
[0018] The preparation method is characterized in that: in steps (a) and (b), the moisture content of the dried particles does not exceed 3%.
[0019] The preparation method is characterized in that: in steps (a) and (b), the wetting agent is 95% ethanol.
[0020] The seaweed polypeptide described in this invention is an off-white powder with a particle size standard of 100% passing through an 80-mesh sieve, a peptide content (on a dry basis) ≥99%, a molecular weight ≤1000 Da, a loss on drying ≤5.0%, an ash content ≤5.0%, pesticide residues not detectable, total heavy metals ≤10 ppm, arsenic content ≤10 ppm, lead content ≤10 ppm, total bacterial count ≤1000 cfu / g, yeast and mold ≤100 cfu / g, Escherichia coli not detectable, Salmonella not detectable, and Staphylococcus not detectable.
[0021] Beneficial effects
[0022] The effervescent tablets of Artemisia annua polypeptide provided by this invention have a simple process, controllable cost, good taste, and good stability, making them suitable for children, the elderly, and people with swallowing difficulties. This invention provides a feasible industrialization solution for the dosage form transformation of Artemisia annua polypeptide. Detailed Implementation
[0023] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. The following description of at least one exemplary embodiment is merely illustrative and is in no way intended to limit the present invention or its application or use. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0024] The following is a description of the Artemisia annua polypeptide used in this invention: The manufacturer is Xi'an Muguo Biotechnology Co., Ltd., product batch number: MG-2024081502. It is an off-white powder with a particle size standard of 100% passing through an 80-mesh sieve. The peptide content (on a dry basis) is 99.07%, molecular weight ≤1000 Da, loss on drying is 0.79%, ash content is 1.42%, pesticide residues were not detected, total heavy metals ≤10 ppm, arsenic content ≤10 ppm, lead content ≤10 ppm, total bacterial count ≤1000 cfu / g, yeast and mold ≤100 cfu / g, Escherichia coli, Salmonella, and Staphylococcus were not detected.
[0025] Example 1
[0026] 1. The preliminary prescription is as follows:
[0027] Element effect Prescription percentage (%) Artemisia annua polypeptide Main drug 25.75 Xylitol diluent 19.46 Anhydrous citric acid Acidic disintegrants 23.18 Sodium bicarbonate alkaline disintegrants 30.40 Polyethylene glycol 6000 lubricant 0.50 Steviosides Flavoring agents 0.71
[0028] 2. The preliminary preparation method is as follows:
[0029] Seaweed extract, anhydrous citric acid, and sodium bicarbonate were each passed through a 60-mesh sieve, and the required dosages were weighed separately. Anhydrous citric acid was mixed with 50% of the prescribed amount of seaweed extract, and an appropriate amount of 95% ethanol was added to granulate the mixture. The granules were then passed through a 40-mesh sieve and dried at 65°C under normal pressure until the moisture content was ≤3%, and then passed through another 40-mesh sieve to obtain acid granules. Separately, 50% of the seaweed extract was mixed with sodium bicarbonate, and 95% ethanol was added to granulate the mixture. The mixture was then passed through a 40-mesh sieve and dried at 65°C under normal pressure until the moisture content was ≤3%, and then passed through another 40-mesh sieve to obtain alkali granules. Finally, the acid granules, alkali granules, diluent, lubricant, and flavoring agent were mixed thoroughly. A 6.0mm shallow concave die was used, and the target tablet weight was 120mg. The tablets were then compressed using a tableting machine.
[0030] 3. The calculation and measurement methods for some evaluation indicators are as follows:
[0031] 3.1 Disintegration Time Limit
[0032] According to the 2020 edition of the Chinese Pharmacopoeia, section 0921, the disintegration time test method is used: Take one tablet and place it in a 250ml beaker (containing 200ml of water at 20℃±5℃). Numerous bubbles will be released. When the gas escaping from the tablet or fragments ceases, the tablet should dissolve or disperse in the water, leaving no aggregated particles. Unless otherwise specified, test six tablets using the same method; each tablet should disintegrate within 5 minutes. If one tablet fails to disintegrate completely, six more tablets should be tested again, and all should meet the requirements.
[0033] 3.2 Taste score
[0034] Effervescent tablets were dissolved completely in warm water at a ratio of 1g tablet to 50ml of water. Ten healthy volunteers aged 20-30 years were selected to taste the effervescent solution and give an overall taste rating out of 100. The average score was taken.
[0035] 3.3 Angle of repose
[0036] The angle of repose of the particles was measured using the BT-1001 intelligent powder property tester from Dandong Better Instruments Co., Ltd., as a characterization of particle flowability.
[0037] Example 2: Screening of Prescription Composition
[0038] 1. Selection of diluent types
[0039] The diluents investigated were xylitol, lactose, and microcrystalline cellulose. The diluent dosages were as specified in the preliminary formulation. Other material types and dosages were also consistent with the preliminary formulation. Three groups of samples were prepared using the preliminary preparation method, ensuring a common tablet hardness range of 50-70 N. The target tablet weight for all three groups was 120 mg, and the tablets were round with a diameter of 6 mm. Suitable diluents were screened by comparing the flowability of the total mixed particles (i.e., the total mixture before tableting) and the disintegration time of the finished product. The results are shown in Table 1 below.
[0040] Table 1 Results of the screening of diluent types
[0041] Types of diluents lactose Xylitol microcrystalline cellulose Angle of repose (°) 21.78 22.22 30.77 Disintegration time (s) 85 116 64
[0042] The results in the table above show that when the diluents were xylitol, lactose, and microcrystalline cellulose, the total mixed particles exhibited good flowability (angle of repose < 40°) and disintegration time < 5 min, indicating that xylitol, lactose, and microcrystalline cellulose can all be used as diluents for this product. Lactose will be temporarily selected as the diluent for further investigation.
[0043] 2. Screening of alkaline disintegrants
[0044] Anhydrous citric acid was used as the acidic disintegrant. Sodium carbonate, sodium bicarbonate, and calcium carbonate were investigated as alkaline disintegrants, with lactose chosen as the diluent. Other materials were selected and their dosages were the same as in the preliminary formulation. Three groups of samples were prepared according to the preliminary preparation method, ensuring a common tablet hardness range of 50-70 N. The target tablet weight for all three groups was 120 mg, and the tablets were round with a diameter of 6 mm. Suitable alkaline disintegrants were screened by comparing the taste, disintegration time, and state of the effervescent solution. The results are shown in Table 2 below.
[0045] Table 2. Screening Results of Alkaline Disintegrants
[0046] Types of disintegrants Sodium carbonate Calcium carbonate Sodium bicarbonate Taste rating 86 71 92 Disintegration time (s) 87 137 85 The state of the solution after disintegration clarify The solution turned white and felt slippery. clarify
[0047] The results in the table above show that when sodium carbonate and sodium bicarbonate are used as alkaline disintegrants, the prepared sample disintegration solutions have a good taste, the disintegration time is less than 5 minutes, and the solutions are clear after disintegration. Therefore, both sodium carbonate and sodium bicarbonate can be used as alkaline disintegrants for this product. Sodium bicarbonate will be selected for further investigation for the time being.
[0048] 3. Screening of disintegrant ratios
[0049] Lactose was chosen as the diluent, and sodium bicarbonate as the alkaline disintegrant. The sum of alkaline and acidic disintegrants in the fixed formulation was 53.58%. The ratios of alkaline to acidic disintegrants were investigated at 1.31:1 (30.40%:23.18%), 1.11:1 (28.19%:25.40%), and 1.51:1 (32.24%:21.35%). Other materials and their amounts remained the same as in the preliminary formulation. Three groups of samples were prepared according to the preliminary preparation method, ensuring a common tablet hardness range of 50-70 N. The target tablet weight was 120 mg, and the tablets were round with a diameter of 6 mm. A suitable diluent was screened by comparing the flowability of the total mixed particles and the disintegration time of the finished product. The results are shown in Table 3 below.
[0050] Table 3. Screening results of disintegrant ratios
[0051] The ratio of alkaline disintegrants to acidic disintegrants 1.11：1 1.31：1 1.51：1 Angle of repose (°) 31.53 21.78 20.78 Disintegration time (s) 76 85 86
[0052] The results in the table above show that when the ratio of alkaline disintegrant to acidic disintegrant is 1.11:1, 1.31:1, and 1.51:1, the total mixed particles exhibit good flowability, and the disintegration time meets the requirements of the Chinese Pharmacopoeia, with relatively rapid disintegration. Therefore, the acceptable range for the ratio of alkaline to acidic disintegrant in this product is (1.11–1.51):1. For now, a ratio of 1.11:1 (28.19%:25.40%) is selected for further investigation.
[0053] 4. Screening of flavoring agents
[0054] Lactose was chosen as the diluent, and sodium bicarbonate was chosen as the alkaline disintegrant. The ratio of alkaline to acidic disintegrant was 1.11:1 (28.19%:25.40%). The flavoring agents investigated were steviol glycosides, strawberry flavor, and orange flavor, all at a dosage of 0.71%. Other materials and dosages were the same as in the preliminary formulation. Three groups of samples were prepared according to the preliminary preparation method, controlling the tablet hardness of all three groups to be within the common range of 50-70 N. The target tablet weight was 120 mg, and the tablets were round with a diameter of 6 mm. Suitable flavoring agents were screened by comparing the disintegration time of the finished product and the taste of the solution after disintegration. The results are shown in Table 4 below.
[0055] Table 4. Results of the screening of flavoring agent types
[0056] Types of flavoring agents Steviosides strawberry flavoring Orange flavoring Disintegration time (s) 86 85 92 Taste rating 93 86 88
[0057] The results in the table above show that when the flavoring agents are steviol glycosides, strawberry flavor, and orange flavor, the disintegration times of the samples all meet the requirements of the 2020 edition of the Chinese Pharmacopoeia, and the disintegration is relatively rapid. The effervescent solutions all have a good taste. Therefore, steviol glycosides, strawberry flavor, and orange flavor can all be used as flavoring agents for this product. We will tentatively select steviol glycosides as the flavoring agent for further investigation.
[0058] 5. Selection of Lubricant Types
[0059] Lactose was chosen as the diluent, sodium bicarbonate as the alkaline disintegrant, and the ratio of alkaline to acidic disintegrant was 1.11:1 (28.19%; 25.40%). Stevioside was chosen as the flavoring agent. The effects of three lubricants—polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000—were compared. The lubricant dosage was fixed at 0.50%, and the types and amounts of other materials were the same as in the preliminary formulation. Three groups of samples were prepared according to the preliminary preparation method, controlling the three groups of samples to have a common tablet hardness range of 50-70 N. The target tablet weight was 120 mg, and the tablets were round with a diameter of 6 mm. A suitable lubricant was screened by comparing the flowability of the total mixed particles and the disintegration time of the finished product. The results are shown in Table 5 below.
[0060] Table 5 Results of Lubricant Type Screening
[0061] Types of lubricants Polyethylene glycol 4000 Sodium benzoate Polyethylene glycol 6000 Angle of repose (°) 28.48 28.00 31.50 Effervescence time (s) 134 128 142
[0062] The results in the table above show that when polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000 are used as lubricants, the total particle flowability of the prepared samples is good, the disintegration time meets the requirements of the 2020 edition of the Chinese Pharmacopoeia, and the disintegration is relatively fast. Therefore, polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000 can all be used as lubricants for this product. Polyethylene glycol 6000 is temporarily selected as the lubricant for further investigation.
[0063] Based on the above experimental screening, the formulation composition of this product is determined as follows:
[0064] Element effect Prescription percentage (%) Artemisia annua polypeptide Main drug 25.75 Xylitol diluent 19.46 Anhydrous citric acid Acidic disintegrants 25.40 Sodium bicarbonate alkaline disintegrants 28.19 Polyethylene glycol 6000 lubricant 0.50 Steviosides Flavoring agents 0.71
[0065] Note: The diluents for this product can be selected from xylitol, lactose, and microcrystalline cellulose; the alkaline disintegrants for this product can be selected from sodium carbonate and sodium bicarbonate; the total proportion of disintegrants in the formulation of this product is 53.58%, and the ratio of alkaline disintegrants to acidic disintegrants can be selected from (1.11 to 1.51):1; the flavoring agents for this product can be selected from steviol glycosides, strawberry flavor, and orange flavor; the lubricants for this product can be selected from polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000.
[0066] Example 3: Investigation of the preparation process
[0067] 1. Investigation on the moisture content of dried acid and alkali granules
[0068] Samples were prepared according to the formulation selected above. The acid and alkali particles from the same group of samples were dried to achieve moisture contents of 0–1%, 1–2%, and 2–3%, respectively. Other product preparation steps were the same as the initially proposed preparation method. Three groups of samples were prepared using the above method, controlling the tablet hardness of all three groups to be within the common range of 50–70 N. The target tablet weight for each group was 120 mg, and the tablets were round with a diameter of 6 mm. The appropriate moisture content for drying the acid and alkali particles was screened by comparing the disintegration time of the finished products. The results are shown in Table 6 below.
[0069] Table 6. Screening Results of Drying Moisture Content of Acid and Base Particles
[0070] Moisture content 0～1％ 1～2％ 2～3％ Disintegration time (s) 124 105 67
[0071] As shown in the table above, when the dry moisture content of the acid and alkali granules is in the range of 0-3%, the disintegration time of the finished product meets the requirements of the 2020 edition of the Chinese Pharmacopoeia, and the disintegration is relatively fast. Therefore, the standard for the dry moisture content of the acid and alkali granules of this product is set at 0-3%.
[0072] 2. Examination of tablet hardness range
[0073] Samples were prepared according to the selected formulation. The moisture content of the acid and alkali granules was 0–3%, and the tablet hardness ranges were 50–60 N, 61–70 N, and 71–80 N, respectively. Other preparation methods were the same as the initially proposed method. Three groups of samples were prepared according to the above method, and the target tablet weight of all three groups of samples was controlled to be 120 mg. The tablets were round with a diameter of 6 mm. The appropriate tablet hardness range was screened by comparing the disintegration time of the finished products. The results are shown in Table 7 below.
[0074] Table 7 Results of tablet compression hardness range screening
[0075]
[0076] As shown in the table above, the tablet hardness range of the product is 50-80N, and the disintegration time of the product meets the requirements of the 2020 edition of the Chinese Pharmacopoeia. Moreover, the disintegration is relatively fast. Therefore, the tablet hardness standard of this product is determined to be 50-80N.
[0077] Based on the above findings, the preparation method for this product is determined as follows:
[0078] Seaweed extract, anhydrous citric acid, and sodium bicarbonate were each passed through a 60-mesh sieve, and the required dosages were weighed separately. Anhydrous citric acid was mixed with 50% of the prescribed amount of seaweed extract, and an appropriate amount of 95% ethanol was added to granulate the mixture. The granules were then passed through a 40-mesh sieve and dried at 65°C under normal pressure until the moisture content was ≤3%, and then passed through another 40-mesh sieve to obtain acid granules. Separately, 50% of the seaweed extract was mixed with sodium bicarbonate, and 95% ethanol was added to granulate the mixture. The mixture was then passed through a 40-mesh sieve and dried at 65°C under normal pressure until the moisture content was 43%, and then passed through another 40-mesh sieve to obtain alkali granules. Finally, the acid granules, alkali granules, diluent, lubricant, and flavoring agent were mixed thoroughly. A 6.0mm shallow concave die was used, with a target tablet weight of 120mg and a target tablet hardness range of 50-80N. The tablets were then compressed using a tableting machine to obtain the final product.
[0079] Example 4 Quality Evaluation
[0080] According to the above-determined prescription and preparation process, a large batch of 5000 tablets was prepared. After tableting, samples were taken for the following tests.
[0081] 1. Appearance and properties
[0082] This product consists of pale yellow, round tablets with a smooth surface and uniform color. It has the characteristic odor of the raw material, a slightly sweet taste, and no off-odors. It disintegrates rapidly upon contact with water, producing uniform, dense bubbles. Initially, there is a vigorous reaction at the bottom of the container, accompanied by a brief period of tablet floating. After disintegration, the solution is clear and transparent, pale yellow, with no visible insoluble matter.
[0083] 2. Tablet weight difference
[0084] Referring to the determination method in the 2020 edition of the Chinese Pharmacopoeia, take 20 tablets of Artemisia annua polypeptide effervescent tablets prepared according to the above-screened prescription and preparation process, accurately weigh the total weight, calculate the average tablet weight, and then accurately weigh each tablet separately. Compare the weight of each tablet with the average tablet weight. According to the provisions in the table, no more than 2 tablets shall exceed the weight difference limit, and no tablet shall exceed the limit by 1 time.
[0085] Average tablet weight or labeled tablet weight / g Quality variation limit / % Less than 0.30g ±7.5％ 0.30g and above ±5％
[0086] Following the above method, the following weights (in grams) of 20 tablets were weighed: 0.1272, 0.1209, 0.1142, 0.1278, 0.1179, 0.1208, 0.1252, 0.1212, 0.1178, 0.1158, 0.1178, 0.1253, 0.1285, 0.1131, 0.1117, 0.1285, 0.1116, 0.1185, 0.1241, 0.1189. Based on the above criteria, the tablet weight variation of this product is acceptable.
[0087] 3. Disintegration time limit
[0088] According to the 2020 edition of the Chinese Pharmacopoeia, section 0921, the disintegration time test method is used: Take one tablet and place it in a 250ml beaker (containing 200ml of water at 20℃±5℃). Numerous bubbles will be released. When the gas escaping from the tablet or fragments stops, the tablet should dissolve or disperse in the water, leaving no aggregated particles. Unless otherwise specified, test six tablets using the same method; each tablet should disintegrate within 5 minutes. If one tablet fails to disintegrate completely, six more tablets should be tested again, and all should meet the requirements.
[0089] Six tablets were randomly sampled, and the disintegration times were measured to be 131 seconds, 127 seconds, 140 seconds, 133 seconds, 127 seconds, and 126 seconds, which meet the requirements of the 2020 edition of the Chinese Pharmacopoeia and are qualified for the disintegration time limit.
[0090] 4. Stability Test
[0091] The prepared samples were sealed in effervescent tablet bottles and placed at 37℃±2℃ and relative humidity 75%±5% for 3 months. The quality of the products was then examined, and the results are as follows:
[0092]
[0093] Example 5: Magnification Study
[0094] Following the established prescription and preparation process, effervescent tablets containing Artemisia annua polypeptide, weighing 2.4g, were prepared using a 24.0mm shallow concave die. Six tablets were randomly sampled, and their disintegration times were 152 seconds, 143 seconds, 139 seconds, 146 seconds, 135 seconds, and 147 seconds, respectively. These disintegration times met the requirements of the 2020 edition of the Chinese Pharmacopoeia. Twenty tablets were randomly sampled for further testing, and the variation in tablet weight also met the requirements of the 2020 edition of the Chinese Pharmacopoeia.
[0095] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A kind of seaweed seed polypeptide effervescent tablet, characterized in that, It is composed of the following components by mass percentage: 20%–30% seaweed polypeptide, 15%–22% diluent, 20%–30% anhydrous citric acid, 25%–33% alkaline disintegrant, 0.1%–1.0% lubricant, and 0.1%–1.0% flavoring agent; wherein the alkaline disintegrant is selected from sodium bicarbonate or sodium carbonate; the sum of the mass percentages of all components is 100%.
2. The Artemisia annua polypeptide effervescent tablet as described in claim 1, characterized in that: The diluent is selected from at least one of xylitol, lactose, and microcrystalline cellulose.
3. The Artemisia annua polypeptide effervescent tablet as described in claim 1, characterized in that: The lubricant is selected from at least one of polyethylene glycol 4000, sodium benzoate, and polyethylene glycol 6000.
4. The Artemisia annua polypeptide effervescent tablet as described in claim 1, characterized in that: The flavoring agent is selected from at least one of steviol glycosides, strawberry flavoring, and orange flavoring.
5. The Artemisia annua polypeptide effervescent tablet as described in claim 1, characterized in that: The mass ratio of the alkaline disintegrant to anhydrous citric acid is (1.11 to 1.51):
1.
6. A method for preparing the Artemisia annua polypeptide effervescent tablets according to any one of claims 1-5, characterized in that, Includes the following steps: (a) The acidic components (anhydrous citric acid and 50% of the prescribed amount of Artemisia annua polypeptide) were mixed with a wetting agent, granulated, dried, and sized to obtain acid granules; (b) The alkaline component (alkaline disintegrant and 50% of the prescribed amount of Artemisia annua polypeptide) is mixed with a wetting agent, granulated, dried, and granulated to obtain alkaline granules; (c) Mix the acid particles, alkali particles, diluent, lubricant, and flavoring agent evenly; (d) Compress the tablets to obtain the final product.
7. The method as described in claim 6, characterized in that: In steps (a) and (b), the moisture content of the dried particles does not exceed 3%.
8. The method as described in claim 6, characterized in that: In steps (a) and (b), the wetting agent is 95% ethanol.